Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • Entinostat (MS-275): Applied Protocols for Epigenetic Can...

    2025-11-24

    Entinostat (MS-275): Applied Protocols for Epigenetic Cancer Research

    Overview: Principle and Rationale of Entinostat in Oncology Workflows

    Entinostat (MS-275, SNDX-275) is a potent, orally available class I histone deacetylase (HDAC) inhibitor, selectively targeting HDAC1, HDAC3, and—at much higher concentrations—HDAC8. Its mechanism centers on epigenetic modulation: by inhibiting the histone deacetylase signaling pathway, Entinostat reactivates tumor suppressor gene expression and disrupts oncogenic programs, resulting in cancer cell proliferation inhibition and apoptosis induction. This dual-action profile makes Entinostat a cornerstone for both mechanistic and translational cancer research, leveraging its robust anti-proliferative effects observed across diverse cell lines (breast, colon, lung, myeloma, ovary, pancreas, prostate, leukemia) and in in vivo tumor models.

    APExBIO supplies Entinostat as a solid compound (SKU: A8171), with validated purity and rigorous storage requirements to ensure experimental reproducibility. Its clinical relevance is underscored by studies showing efficacy in retinoblastoma treatment research and tolerable profiles in solid tumor clinical trials, positioning it as a translational bridge from bench to bedside.

    Step-by-Step Experimental Workflow and Protocol Enhancements

    1. Preparation and Handling

    • Dissolution: Entinostat is insoluble in water but dissolves readily in DMSO (≥18.8 mg/mL) and ethanol (≥7.4 mg/mL, with ultrasonic assistance). For maximal solubility, warming to 37°C and ultrasonic agitation are recommended. Avoid prolonged exposure to room temperature to preserve compound integrity.
    • Stock Solutions: Prepare concentrated stocks in DMSO; aliquot and store at -20°C. Stock solutions are stable for several months, but avoid repeated freeze-thaw cycles. Long-term storage of working solutions is discouraged to prevent degradation.

    2. Cell-Based Assays

    • Dosing and Treatment: For most cancer cell lines, begin with a dose-response range (e.g., 0.01–10 μM) to empirically determine IC50 values. Literature reports IC50 values of 0.368 μM for HDAC1 and 0.501 μM for HDAC3, providing a rational starting point. For HDAC8, activity is observed at much higher concentrations (IC50 ≈ 63.4 μM).
    • Assay Selection: To distinguish between proliferative arrest and apoptosis induction, combine metabolic viability assays (e.g., MTT, CellTiter-Glo) with apoptosis-specific readouts (e.g., Annexin V/PI staining, caspase-3/7 activation). This dual-metric approach aligns with contemporary recommendations for in vitro drug response evaluation.

    3. Chromatin and Gene Expression Analysis

    • Histone Acetylation: Quantify global and locus-specific histone acetylation by Western blot, ChIP-qPCR, or ChIP-seq. Increased acetyl-histone levels in treated samples confirm target engagement and pathway inhibition.
    • Gene Expression: Use RT-qPCR or RNA-seq to monitor reactivation of tumor suppressor genes and repression of oncogenes following Entinostat treatment. Select gene panels based on cancer type and intended mechanistic focus.

    4. Advanced Functional Assays

    • Cell Cycle Analysis: Employ flow cytometry (e.g., PI or DAPI staining) to detect G1 arrest, a hallmark of Entinostat’s cytostatic effect.
    • Reactive Oxygen Species (ROS) Measurement: Use DCFDA or similar probes to quantify ROS induction—a mediator of Entinostat-driven apoptosis.

    Advanced Applications and Comparative Advantages

    Entinostat’s unique pharmacological profile as an oral histone deacetylase inhibitor enables several advanced research applications:

    • Retinoblastoma Treatment Research: Systemic administration in murine and rat models increases acetyl-histone levels in retinal tissue and significantly reduces tumor burden, providing a robust platform for preclinical drug validation and mechanistic studies.
    • Combination Therapies: Clinical phase I studies demonstrate that Entinostat can be safely co-administered with agents such as 13-cis retinoic acid (CRA) in advanced solid tumor settings, supporting combinatorial epigenetic strategies.
    • Epigenetic Modulation in Oncology: The compound’s selectivity for HDAC1 and HDAC3 allows researchers to dissect the roles of specific HDAC isoforms in tumorigenesis and therapy resistance, complementing pan-HDAC inhibitor studies.
    • Precision Oncology: Entinostat’s mechanistic basis in tumor suppressor gene regulation and histone deacetylase pathway targeting aligns with precision medicine approaches, enabling rational design of patient-specific therapeutic regimens.

    For researchers seeking deeper mechanistic or translational insights, several thought-leadership articles provide complementary perspectives:

    Troubleshooting and Optimization Tips

    • Solubility Issues: If precipitation is observed, confirm use of appropriate solvent (DMSO/ethanol) and sufficient warming/ultrasonication. Avoid aqueous diluents at stock concentrations.
    • Batch Variability: Always verify lot-specific purity and perform a small pilot assay with each new vial of Entinostat to ensure consistent HDAC inhibition and biological activity.
    • Assay Interference: DMSO concentrations above 0.1% (v/v) in final culture media can affect cell viability and confound results. Prepare serial dilutions to minimize solvent carryover.
    • Apoptosis Versus Proliferation Inhibition: Disambiguate cytostatic from cytotoxic effects by coupling cell viability assays with direct apoptosis markers (e.g., caspase activity, Annexin V), as recommended by Schwartz (2022) in her dissertation on drug response evaluation.
    • Long-Term Storage: Store aliquots at -20°C and avoid thaw-refreeze cycles. Discard working solutions after one month, even if stored under optimal conditions.
    • In Vivo Dosing: Consult published preclinical protocols for relevant dosing schedules and monitor systemic toxicity, especially when combining Entinostat with other agents.

    Future Outlook: Integrating Entinostat Into Next-Generation Cancer Research

    As the landscape of epigenetic modulation in oncology evolves, Entinostat (MS-275, SNDX-275) remains at the forefront for its selectivity and translational potential. Future directions include:

    • Single-Cell Epigenomics: Integrating Entinostat treatment with single-cell sequencing platforms will enable high-resolution mapping of chromatin and transcriptomic changes in tumor subpopulations.
    • Combination with Immunotherapies: Ongoing trials are investigating synergy between HDAC1 and HDAC3 inhibitors and immune checkpoint blockade, leveraging Entinostat-driven changes in tumor immunogenicity.
    • Systems Biology and AI: Multi-omics and machine learning approaches are being applied to predict Entinostat responders and optimize dosing regimens, as highlighted in systems-level analyses.
    • Clinical Translation: As more robust in vitro models are developed, including 3D cultures and patient-derived organoids, Entinostat’s value in forecasting clinical responses will increase.

    For researchers aiming to harness the full potential of epigenetic therapeutics in precision oncology, Entinostat (MS-275, SNDX-275) from APExBIO offers validated performance, reliable supply, and extensive application support.

    References